Biopharm Australia
Biopharm Australia is an Australian pharmaceutical company. Founded in the 1980s, Biopharm Australia develops sulfated polysaccharides for use in veterinary medicine and has ongoing research and development commitments in osteoarthritis, musculoskeletal diseases and cancer.
Biopharm Australia pioneered the veterinary development of sodium pentosan polysulfate as a disease-modifying osteoarthritis drug (DMOAD) under the brand Cartrophen. The company invests heavily in the research and development of medicines that improve animal quality of life and strengthen the human-animal bond.
History
Biopharm Australia was incorporated in 1987 in Sydney, Australia. It was established to advance healthy treatments for osteoarthritis. Biopharm Australia aims to improve animal health through the development and use of the best technology. Cartrophen Vet is a sodium pentosan polysulfate for the treatment of osteoarthritis (OA), also known as degenerative joint disease.
In the late 1980s, Biopharm Australia began collaborating on osteoarthritis treatments. It was registered under licence in Australia as Anarthron. In 1989, Cartrophen Vet was registered in Australia and New Zealand. In the 1990s, Biopharm Australia achieved registrations in Europe and North America, including the United Kingdom, Ireland, Finland and Canada.
In the 2000s, Cartrophen Vet was registered in Austria*, Belgium*, Denmark, Germany, France*, the Netherlands*, Sweden and Japan. The horse equivalent product, Cartrophen Equine Forte, was registered in New Zealand and the United Arab Emirates.
In the early 2010s, Cartrophen Equine Forte was registered in Australia. At the same time, Biopharm's product Cartrophen Vet achieved registrations in Poland, Norway, Iceland, Switzerland*, Argentina and Chile.
Registrations Cartrophen Vet
2017: Cartrophen Vet is registered in 20 countries, including Australia, New Zealand, the United Kingdom, Ireland, Finland, Canada, Austria*, Belgium*, Denmark, Germany, France*, the Netherlands*, Sweden, Japan, Poland, Norway, Iceland, Switzerland*, Brazil, Argentina and Chile.
Registrations Cartrophen Equine Forte
2014: Cartrophen Equine Forte is registered in Australia, New Zealand and the United Arab Emirates.
[*Cartrophen Vet is registered as Anarthron in these countries]
Products
Cartrophen products are for the treatment of non-infectious inflammatory joint disease in dogs and horses. Biopharm's testing laboratories are licensed by the Therapeutic Goods Administration (TGA). The TGA is the official inspection service for veterinary products. The TGA is internationally recognised under mutual recognition agreements, e.g. with the EEC.
Cartrophen Vet (for dogs and horses)
Cartrophen Vet is approved for use in dogs in all countries where registered and is also approved for use in horses only in Australia, New Zealand, Argentina and Chile. It contains 100 mg/mL sodium pentosan polysulfate.
Cartrophen Equine Forte (for horses)
It contains 250 mg/mL of sodium pentosan polysulfate and is approved in Australia, New Zealand and the United Arab Emirates.
External links
 | This article about an Australian corporation or company is a stub. You can help EverybodyWiki by expanding it. |
This article "Biopharm Australia" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Biopharm Australia. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
